Difference between revisions of "Rituximab-abbs (Truxima)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "http://www.gene.com/" to "https://www.gene.com/")
 
(3 intermediate revisions by 2 users not shown)
Line 6: Line 6:
 
<br>Extravasation: [[neutral]]
 
<br>Extravasation: [[neutral]]
 
*[[Rituximab (Rituxan) desensitization protocol]]
 
*[[Rituximab (Rituxan) desensitization protocol]]
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
Line 35: Line 35:
 
</div>
 
</div>
 
==Patient drug information==
 
==Patient drug information==
−
*[http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf Rituximab (Rituxan) package insert]
+
*[https://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf Rituximab (Rituxan) package insert]
 
*[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]</ref>
 
*[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref>
Line 46: Line 46:
  
 
==Also known as==
 
==Also known as==
−
*'''Brand names:''' Truxima
+
*'''Code name:''' CT-P10
 +
*'''Brand name:''' Truxima
  
 
==References==
 
==References==

Latest revision as of 00:49, 1 July 2024

Note: this is an FDA-approved biosimilar. The information below is reproduced from the Rituximab (Rituxan) page, except for the details of FDA indication.

General information

Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 2018-11-28: Initial approval for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.
  • 2018-11-28: Initial approval for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy.
  • 2018-11-28: Initial approval as single-agent maintenance therapy for the treatment of adult patients with follicular, CD20-positive, B-cell NHL achieving a complete or partial response to a rituximab product in combination with chemotherapy.
  • 2018-11-28: Initial approval for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.

Also known as

  • Code name: CT-P10
  • Brand name: Truxima

References

  1. ↑ Rituximab (Rituxan) patient drug information (Chemocare)
  2. ↑ Rituximab (Rituxan) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Rituximab-abbs_(Truxima)&oldid=87924"